The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
US clinical-stage biotech Pieris Pharmaceuticals (Nasdaq: PIRS) today announced the promotions of Thomas Bures to chief financial officer and Ahmed Mousa to chief business officer. 6 October 2021
Johnson & Johnson has announced a new analysis of Stelara (ustekinumab), using safety data from 13 clinical studies across approved indications. 6 October 2021
Healthcare giant Johnson & Johnson has submitted data to the US Food and Drug Administration (FDA) to support use of a booster shot of its COVID-19 vaccine in adults. 6 October 2021
Japan’s largest drugmaker Takeda Pharmaceutical saw its shares fall 6.4% to 3,340 yen this morning, after it revealed that a safety signal has emerged in Phase II studies of TAK-994, an investigational oral orexin agonist. 6 October 2021
New research conducted by Pfizer and published in The Lancet shows effectiveness of the firm’s coronavirus jab waning over time, although not due to the Delta variant of the virus. 6 October 2021
German family-owned drug major Boehringer Ingelheim today inaugurated its state-of-the-art biopharmaceutical production facility Large Scale Cell Culture (LSCC) in Vienna, Austria. 6 October 2021
USA-based microbiome company Vedanta Biosciences says that its Phase II clinical trial of VE303, an orally administered investigational live biotherapeutic product in development for the prevention of recurrent Clostridium difficile infection (CDI) in high-risk patients, met its primary endpoint of preventing disease recurrence through Week 8. 6 October 2021
Australia’s Therapeutic Goods Administration (TGA) has granted provisional determination to the local subsidiary of US pharma giant Pfizer in relation to a new combination therapy containing PF-07321332 and ritonavir, for the treatment of adult patients with symptomatic, confirmed coronavirus infection. 6 October 2021
Spanish plasma specialist Grifols says it has closed its issuance of senior unsecured notes for the equivalent of 2 billion euros ($2.32 billion) to finance its investment in Biotest AG.
The issuance, launched on September 6 October 2021
For the first time in 20 years, a new therapy for sickle cell disease is to be made available on the UK's National Health Service (NHS). 5 October 2021
Ireland-headquartered biotech Horizon Therapeutics has announced the publication of a post-hoc analysis from the N-MOmentum Phase II/III pivotal trial of Uplizna (inebilizumab-cdon), which highlights a sustained effect on attack risk with no new safety signals in people with neuromyelitis optica spectrum disorder (NMOSD) who received the treatment for four or more years. 5 October 2021
US biotech Xencor saw its shares gain 5.5% by close of trading and a further 2% to $36.23 after hours, following its revelation of a second deal with US health care giant Johnson & Johnson. 5 October 2021
The global antibacterial drugs market is projected to grow at a modest compound annual growth rate (CAGR) of 2.6% between 2021 and 2031, according to a Fact MR report. 5 October 2021
UK pharma major AstraZeneca has submitted a request to the US Food and Drug Administration for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of symptomatic COVID-19. 5 October 2021
The list of rare (orphan) diseases, which consists of more than 200 diseases in Russia, needs to be updated, according to recent statements by Galina Izotova, deputy chairman of the Russian Audit Chamber. 5 October 2021
US biotech Enanta Pharmaceuticals has delivered an update on its two clinical stage farnesoid X receptor (FXR) agonists, EDP-305 and EDP-297, in non-alcoholic steatohepatitis (NASH). 5 October 2021
Pushing ahead in the race to develop a vaccine for respiratory syncytial virus (RSV), Johnson & Johnson has announced impressive Phase II data and the initiation of late-stage testing. 5 October 2021
Xenon Pharmaceuticals saw its shares rise more than a 100% in regular trading and a further 5% to $33.01 after-hours yesterday, as it released encouraging clinical results with its epilepsy candidate. 5 October 2021
The European Medicines Agency’s human medicines committee (CHMP) has concluded that an extra dose of the COVID-19 vaccines Comirnaty, from Pfizer and BioNTech, as well as Spikevax, marketed by Moderna, may be given to people with severely weakened immune systems, at least 28 days after their second dose. 5 October 2021
The illegal drug market in Russia is estimated to be worth 15–20 billion roubles ($205-274 million), according to a recent study, conducted by analysts at RNC Pharma, one of Russia’s leading pharma analytics agencies. 5 October 2021